ESC26: AstraZeneca’s heart failure drug shows promise in ph. 2 trial

Posted inBiotechnology

AstraZeneca’s oral relaxin agonist delivered encouraging phase 2b results in chronic heart failure, improving measures of cardiac function across two patient groups.